Back to Journals » International Journal of Nanomedicine » Volume 12

Ex vivo distribution of gold nanoparticles in choroidal melanoma

Authors Kanavi MR, Asadi S, Ahmadieh H

Received 14 March 2017

Accepted for publication 14 October 2017

Published 30 November 2017 Volume 2017:12 Pages 8527—8529

DOI https://doi.org/10.2147/IJN.S136939

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Thomas J Webster

Mozhgan Rezaei Kanavi,1 Somayeh Asadi,1,2 Hamid Ahmadieh2

1Ocular Tissue Engineering Research Center, 2Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Studies on combined radiotherapy and nanoparticles (NPs) have shown that a greater therapeutic ratio can be achieved using gold nanoparticles (GNPs) as radiosensitizing agents within the tumor.1 Recent Monte Carlo studies demonstrated that GNPs enhance the absorbed dose by choroidal melanoma during brachytherapy with sources such as 103Pd and 125I.2 Given that the energy range of these sources is low, NPs with high atomic number can be suitable to yield a higher absorbed dose when used alongside the mentioned sources.3 Although it has been a long time since the merit and priority of using NPs in treating cancer by low-energy sources has been studied, regarding eye cancers a major concern has been the way these NPs would be spread in the ocular tissues. A principal question is the form and method by which the NPs disperse within the intraocular tumor after intralesional injection. Will the NPs be also absorbed by the nearby healthy tissues?

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]